2,389
Views
59
CrossRef citations to date
0
Altmetric
Original Research

Oncolytic measles virus encoding interleukin-12 mediates potent antitumor effects through T cell activation

, , , , , , , & show all
Article: e1285992 | Received 28 Nov 2016, Accepted 18 Jan 2017, Published online: 07 Apr 2017

References

  • Bell, J, McFadden, G. Viruses for tumor therapy. Cell Host Microbe 2014; 15:260-5; PMID:24629333; http://dx.doi.org/10.1016/j.chom.2014.01.002
  • Pol J, Buqué A, Aranda F, Bloy N, Cremer I, Eggermont A, Erbs P, Fucikova J, Galon J, Limacher JM et al. Trial watch-oncolytic viruses and cancer therapy. Oncoimmunology 2016; 5:e1117740; PMID:27057469; http://dx.doi.org/10.1080/2162402X.2015.1117740
  • Kaufman HL, Kohlhapp FJ, Zloza A. Oncolytic viruses: a new class of immunotherapy drugs. Nat Rev Drug Discov 2015; 14:642-62; PMID:26323545; http://dx.doi.org/10.1038/nrd4663
  • Donnelly OG, Errington-Mais F, Steele L, Hadac E, Jennings V, Scott K, Peach H, Phillips RM, Bond J, Pandha H et al. Measles virus causes immunogenic cell death in human melanoma. Gene Ther 2013; 20:7-15; PMID:22170342; http://dx.doi.org/10.1038/gt.2011.205
  • Miyamoto S, Inoue H, Nakamura T, Yamada M, Sakamoto C, Urata Y, Okazaki T, Marumoto T, Takahashi A, Takayama K et al. Coxsackievirus B3 is an oncolytic virus with immunostimulatory properties that is active against lung adenocarcinoma. Cancer Res 2012; 72:2609-21; PMID:22461509; http://dx.doi.org/10.1158/0008-5472.CAN-11-3185
  • Diaconu, I, Cerullo V, Hirvinen ML, Escutenaire S, Ugolini M, Pesonen SK, Bramante S, Parviainen S, Kanerva A, Loskog AS et al. Immune response is an important aspect of the antitumor effect produced by a CD40L-encoding oncolytic adenovirus. Cancer Res 2012; 72:2327-38; PMID:22396493; http://dx.doi.org/10.1158/0008-5472.CAN-11-2975
  • Angelova AL, Grekova SP, Heller A, Kuhlmann O, Soyka E, Giese T, Aprahamian M, Bour G, Rüffer S, Cziepluch C et al. Complementary induction of immunogenic cell death by oncolytic parvovirus H-1PV and gemcitabine in pancreatic cancer. J Virol 2014; 88:5263-76; PMID:24574398; http://dx.doi.org/10.1128/JVI.03688-13
  • Guillerme, JB, Boisgerault N, Roulois D, Ménager J, Combredet C, Tangy F, Fonteneau JF, Gregoire M. Measles virus vaccine-infected tumor cells induce tumor antigen cross-presentation by human plasmacytoid dendritic cells. Clin Cancer Res 2013; 19:1147-58; PMID:23339127; http://dx.doi.org/10.1158/1078-0432.CCR-12-2733
  • Lichty BD, Breitbach CJ, Stojdl DF, Bell JC. Going viral with cancer immunotherapy. Nat Rev Cancer 2014; 14:559-67; PMID:24990523; http://dx.doi.org/10.1038/nrc3770
  • Andtbacka RH, Kaufman HL, Collichio F, Amatruda T, Senzer N, Chesney J, Delman KA, Spitler LE, Puzanov I, Agarwala SS et al. Talimogene laherparepvec improves durable response rate in patients with advanced melanoma. J Clin Oncol 2015; 33:2780-88; PMID:26014293; http://dx.doi.org/10.1200/JCO.2014.58.3377
  • Russell SJ, Peng KW. Measles virus for cancer therapy. Curr Top Microbiol Immunol 2009; 330:213-41; PMID:19203112
  • Grossardt, C, Engeland CE, Bossow S, Halama N, Zaoui K, Leber MF, Springfeld C, Jaeger D, von Kalle C, Ungerechts G. Granulocyte-macrophage colony-stimulating factor-armed oncolytic measles virus is an effective therapeutic cancer vaccine. Hum Gene Ther 2013; 24:644-54; PMID:23642239; http://dx.doi.org/10.1089/hum.2012.205
  • Engeland CE, Grossardt C, Veinalde R, Bossow S, Lutz D, Kaufmann JK, Shevchenko I, Umansky V, Nettelbeck DM, Weichert W et al. CTLA-4 and PD-L1 checkpoint blockade enhances oncolytic measles virus therapy. Mol Ther 2014; 22:1949-59; PMID:25156126; http://dx.doi.org/10.1038/mt.2014.160
  • van de Laar L, Coffer PJ, Woltman AM. Regulation of dendritic cell development by GM-CSF: molecular control and implications for immune homeostasis and therapy. Blood 2012; 119:3383-93; PMID:22323450; http://dx.doi.org/10.1182/blood-2011-11-370130
  • Trinchieri G. Interleukin-12 and the regulation of innate resistance and adaptive immunity. Nat Rev Immunol 2003; 3:133-46; PMID:12563297; http://dx.doi.org/10.1038/nri1001
  • Homey B, Muller A, Zlotnik A. Chemokines: agents for the immunotherapy of cancer? Nat Rev Immunol 2002; 2:175-84; PMID:11913068; http://dx.doi.org/10.1038/nri748
  • Pardoll DM. The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer 2012; 12:252-64; PMID:22437870; http://dx.doi.org/10.1038/nrc3239
  • Haile ST, Dalal SP, Clements V, Tamada K, Ostrand-Rosenberg S. Soluble CD80 restores T cell activation and overcomes tumor cell programmed death ligand 1-mediated immune suppression. J Immunol 2013; 191:2829-36; PMID:23918985; http://dx.doi.org/10.4049/jimmunol.1202777
  • Robbins PF, Kantor JA, Salgaller M, Hand PH, Fernsten PD, Schlom J. Transduction and expression of the human carcinoembryonic antigen gene in a murine colon carcinoma cell line. Cancer Res 1991; 51:3657-62; PMID:1712245
  • Hammond AL, Plemper RK, Zhang J, Schneider U, Russell SJ, Cattaneo R. Single-chain antibody displayed on a recombinant measles virus confers entry through the tumor-associated carcinoembryonic antigen. J Virol 2001; 75:2087-96; PMID:11160713; http://dx.doi.org/10.1128/JVI.75.5.2087-2096.2001
  • Nakamura T. Peng KW, Harvey M, Greiner S, Lorimer IA, James CD, Russell SJ. Rescue and propagation of fully retargeted oncolytic measles viruses. Nat Biotechnol 2005; 23:209-14; PMID:15685166; http://dx.doi.org/10.1038/nbt1060
  • Vincent S, Tigaud I, Schneider H, Buchholz CJ, Yanagi Y, Gerlier D. Restriction of measles virus RNA synthesis by a mouse host cell line: trans-complementation by polymerase components or a human cellular factor(s). J Virol 2002; 76:6121-30; PMID:12021345; http://dx.doi.org/10.1128/JVI.76.12.6121-6130.2002
  • Ungerechts G, Springfeld C, Frenzke ME, Lampe J, Parker WB, Sorscher EJ, Cattaneo R. An immunocompetent murine model for oncolysis with an armed and targeted measles virus. Mol Ther 2007; 15:1991-97; PMID:17712331; http://dx.doi.org/10.1038/sj.mt.6300291
  • Schwarz AJ. Preliminary tests of a highly attenuated measles vaccine. Am J Dis Child 1962; 103:386-9; PMID:13909753
  • Combredet, C, Labrousse V, Mollet L, Lorin C, Delebecque F, Hurtrel B, McClure H, Feinberg MB, Brahic M, Tangy F. A molecularly cloned Schwarz strain of measles virus vaccine induces strong immune responses in macaques and transgenic mice. J Virol 2003; 77:11546-554; PMID:14557640; http://dx.doi.org/10.1128/JVI.77.21.11546-11554.2003
  • Chen DS, Mellman I. Oncology meets immunology: the cancer-immunity cycle. Immunity 2013; 39:1-10; PMID:23890059; http://dx.doi.org/10.1016/j.immuni.2013.07.012
  • Shin, EJ, Wanna GB, Choi B, Aguila D 3rd, Ebert O, Genden EM, Woo SL. Interleukin-12 expression enhances vesicular stomatitis virus oncolytic therapy in murine squamous cell carcinoma. Laryngoscope 2007; 117:210-4; PMID:17204993; http://dx.doi.org/10.1097/01.mlg.0000246194.66295.d8
  • Bortolanza, S, Bunuales M, Otano I, Gonzalez-Aseguinolaza G, Ortiz-de-Solorzano C, Perez D, Prieto J, Hernandez-Alcoceba R. Treatment of pancreatic cancer with an oncolytic adenovirus expressing interleukin-12 in Syrian hamsters. Mol Ther 2009; 17:614-22; PMID:19223865; http://dx.doi.org/10.1038/mt.2009.9
  • Derubertis, BG, Stiles BM, Bhargava A, Gusani NJ, Hezel M, D'Angelica M, Fong Y. Cytokine-secreting herpes viral mutants effectively treat tumor in a murine metastatic colorectal liver model by oncolytic and T-cell-dependent mechanisms. Cancer Gene Ther 2007; 14:590-97; PMID:17431402; http://dx.doi.org/10.1038/sj.cgt.7701053
  • Colombo MP, Trinchieri, G. Interleukin-12 in anti-tumor immunity and immunotherapy. Cytokine Growth Factor Rev 2002; 13:155-68; PMID:11900991; http://dx.doi.org/10.1016/S1359-6101(01)00032-6
  • Lieschke, GJ, Rao, PK, Gately, MK, Mulligan, RC. Bioactive murine and human interleukin-12 fusion proteins which retain antitumor activity in vivo. Nat Biotechnol 1997; 15:35-40; PMID:9035103; http://dx.doi.org/10.1038/nbt0197-35
  • Gately MK, Desai BB, Wolitzky AG, Quinn PM, Dwyer CM, Podlaski FJ, Familletti PC, Sinigaglia F, Chizonnite R, Gubler U et al. Regulation of human lymphocyte proliferation by a heterodimeric cytokine, IL-12 (cytotoxic lymphocyte maturation factor). J Immunol 1991; 147:874-82; PMID:1713608
  • Brunda, MJ, Luistro L, Warrier RR, Wright RB, Hubbard BR, Murphy M, Wolf SF, Gately MK. Antitumor and antimetastatic activity of interleukin 12 against murine tumors. J Exp Med 1993; 178:1223-30; PMID:8104230; http://dx.doi.org/10.1084/jem.178.4.1223
  • Kodama, T, Takeda K, Shimozato O, Hayakawa Y, Atsuta M, Kobayashi K, Ito M, Yagita H, Okumura K. Perforin-dependent NK cell cytotoxicity is sufficient for anti-metastatic effect of IL-12. Eur J Immunol 1999; 29:1390-96; PMID:10229107; http://dx.doi.org/10.1002/(SICI)1521-4141(199904)29:04%3c1390::AID-IMMU1390%3e3.0.CO;2-C
  • Smyth MJ, Taniguchi M, Street SE. The anti-tumor activity of IL-12: mechanisms of innate immunity that are model and dose dependent. J Immunol 2000; 165:2665-70; PMID:10946296; http://dx.doi.org/10.4049/jimmunol.165.5.2665
  • Mlecnik, B, Bindea G, Kirilovsky A, Angell HK, Obenauf AC, Tosolini M, Church SE, Maby P, Vasaturo A, Angelova M et al. The tumor microenvironment and Immunoscore are critical determinants of dissemination to distant metastasis. Sci Transl Med 2016; 8:327ra326; PMID:26912905; http://dx.doi.org/10.1126/scitranslmed.aad6352
  • Chang, J, Cho JH, Lee SW, Choi SY, Ha SJ, Sung YC. IL-12 priming during in vitro antigenic stimulation changes properties of CD8 T cells and increases generation of effector and memory cells. J Immunol 2004; 172:2818-26; PMID:14978082; http://dx.doi.org/10.4049/jimmunol.172.5.2818
  • Medina-Echeverz J, Fioravanti J, Zabala M, Ardaiz N, Prieto J, Berraondo P. Successful colon cancer eradication after chemoimmunotherapy is associated with profound phenotypic change of intratumoral myeloid cells. J Immunol 2011; 186:807-15; PMID:21148040; http://dx.doi.org/10.4049/jimmunol.1001483
  • Calain P, Roux L. The rule of six, a basic feature for efficient replication of Sendai virus defective interfering RNA. J Virol 1993; 67:4822-30; PMID:8392616
  • Radecke F, Spielhofer P, Schneider H, Kaelin K, Huber M, Dötsch C, Christiansen G, Billeter MA. Rescue of measles viruses from cloned DNA. Embo J 1995; 14:5773-84; PMID:8846771
  • Martin A, Staeheli P, Schneider U. RNA polymerase II-controlled expression of antigenomic RNA enhances the rescue efficacies of two different members of the Mononegavirales independently of the site of viral genome replication. J Virol 2006; 80:5708-15; PMID:16731909; http://dx.doi.org/10.1128/JVI.02389-05
  • Andersen CL, Jensen JL, Orntoft TF. Normalization of real-time quantitative reverse transcription-PCR data: a model-based variance estimation approach to identify genes suited for normalization, applied to bladder and colon cancer data sets. Cancer Res 2004; 64:5245-50; PMID:15289330; http://dx.doi.org/10.1158/0008-5472.CAN-04-0496
  • Amsen D, de Visser KE, Town T. Approaches to determine expression of inflammatory cytokines. Methods Mol Biol 2009; 511:107-42; PMID:19347295; http://dx.doi.org/10.1007/978-1-59745-447-6_5

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.